Clinical trials: Psychiatric Illness
Autism Spectrum Disorder
Transcranial Photobiomodulation for Reducing Autism Symptoms in Children - Open Label Study (TPBMASDOL)
The hypothesis of the study is that photobiomodulation reduces symptoms of autism. Participants will be children between the ages of 2 and 7, who have been diagnosed with moderate to severe autism.
- Trial name
- NCT06359080
- Testing
- Cognilum TM: Light Treatment Condition
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- JelikaLite LLC
Opioid-induced Constipation
A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy
The purpose of this study is to determine efficacy and safety of naldemedine for the treatment of opioid-induced constipation in adults with non-malignant chronic pain receiving opioid therapy for ≥ 3 months.
- Trial name
- NCT01443403
- Testing
- Naldemedine
- Where
- 49 sites in United States
- Volunteers
- 244 people
- Sponsor
- Shionogi
Attention-Deficit/Hyperactivity Disorder
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate
This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy.
- Trial name
- NCT01106430
- Testing
- Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
- Where
- 64 sites in United States, Belgium and 8 more
- Volunteers
- 267 people
- Sponsor
- Shire
Schizophrenia
Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia.
- Trial name
- NCT00862992
- Testing
- Cariprazine 3 mg, Cariprazine 6 mg, Cariprazine 12.5 mg
- Where
- Japan
- Volunteers
- 34 people
- Sponsor
- Tanabe Pharma Corporation
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.
- Trial name
- VLZ-MD-22 (NCT02372799)
- Testing
- Vilazodone, Fluoxetine
- Where
- 60 sites in United States, Canada
- Volunteers
- 473 people
- Sponsor
- Forest Laboratories
Benign Prostate Hyperplasia, Erectile Dysfunction
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
The purpose of this study is to see whether tadalafil can reduce the signs and symptoms in men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-Lower Urinary Tract Symptoms (BPH-LUTS) and improve their quality of…
- Trial name
- NCT01937871
- Testing
- 5 mg Tadalafil, 0.2 mg Tamsulosin
- Where
- 14 sites in China
- Volunteers
- 909 people
- Sponsor
- Eli Lilly and Company
Erectile Dysfunction
Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.
This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile…
- Trial name
- NCT00655629
- Testing
- Vardenafil ODT (STAXYN, BAY38-9456)
- Where
- 40 sites in United States, Australia and 2 more
- Volunteers
- 339 people
- Sponsor
- Bayer
Irritability Associated With Autism Spectrum Disorder (ASD)
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
The purpose of this study is to find out about the potential benefits and safety of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.
- Trial name
- NCT04174365
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
The goal of the proposed study, is to adapt a positive emotion intervention for Alzheimer's Disease (AD) caregivers into a self-guided online format that incorporates social connection components and adaptive system feedback…
- Trial name
- SAGE-LEAF (NCT05562583)
- Testing
- SAGE LEAF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- BrightOutcome
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01163266
- Testing
- Vortioxetine
- Where
- 39 sites in United States
- Volunteers
- 462 people
- Sponsor
- Takeda
Depressive Disorder, Major
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
This study is open to adults between 18 and 65 years of age who have depression (major depressive disorder). People with a current depressive episode lasting between 2 months and one and a half years can join the study.
- Trial name
- NCT04937829
- Testing
- 5 mg BI 1569912, 20 mg BI 1569912
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Opioid Induced Constipation
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01207427
- Testing
- ADL5945 0.1 mg, ADL5945 0.25 mg
- Volunteers
- 131 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Schizophrenia, Mania
Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents
The purpose of this trial is to assess the safety, tolerability and pharmacokinetics of aripiprazole tablets following oral administration to children and adolescents.
- Trial name
- NCT00102479
- Testing
- Aripiprazole
- Volunteers
- 21 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Healthy Participants
A Study of the Neurobiology of Depression
Previous research studies have shown that depression is associated with changes in structure and activity in different parts of the brain and that antidepressant medication can affect brain activity in different parts of the…
- Trial name
- NCT01051466
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Sleep Disorders
Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
The purpose of this study is to establish the efficacy and safety of Circadin in children with neurodevelopmental disorders and to determine the dose, this randomized, placebo-controlled study is planned to evaluate the efficacy…
- Trial name
- NCT01906866
- Testing
- Circadin 2/5/10 mg
- Where
- 28 sites in United States, Finland and 3 more
- Volunteers
- 125 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Depressive Disorder
A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder
The purpose of this long-term study is to evaluate the safety and efficacy of duloxetine hydrochloride in Japanese children and adolescents with depressive disorder.
- Trial name
- NCT03395353
- Testing
- Duloxetine Hydrochloride
- Where
- Japan
- Volunteers
- 151 people
- Sponsor
- Shionogi
Phobic Disorders
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).
- Trial name
- NCT02432703
- Testing
- JNJ-42165279
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- Janssen Research & Development, LLC
Tobacco Dependence
Single-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product
A comparison of three products for oral nicotine replacement with respect to pharmacokinetics after single-dose of nicotine.
- Trial name
- NCT01084603
- Testing
- Oral Nicotine, NiQuitinTM Nicotine Lozenge, Nicorette® Nicotine Gum
- Where
- Sweden
- Volunteers
- 45 people
- Sponsor
- McNeil AB
Major Depressive Disorder, Anxiety
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate…
- Trial name
- NCT02013531
- Testing
- Brexpiprazole
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
This study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen.
- Trial name
- NCT01348100
- Testing
- Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.